Business Update

Miraculins successfully detects prostate cancer primary protein biomarker using immunoassay

Published in Cancer Weekly, November 14th, 2006

Miraculins Inc. (MOM), a biotechnology company focused on the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, announced it has successfully detected the primary protein biomarker from its prostate cancer diagnostic using an ELISA-based immunoassay.

The colorimetric based ELISA test that was utilized by the Miraculins' research team was also able to produce results in a sample subset consistent with the diagnostic results observed when using mass spectrometry for detection. The successful measurement of the biomarker using an immunoassay marks the first time that Miraculins has used an alternative diagnostic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry